Intuitive Surgical, Inc. (NASDAQ:ISRG)

Citron Research:
Taylor vs Intuitive court case. Negligence by grossly undertraining doctors in using the da Vinci device, directly leading to catastrophic outcomes for patients.

Their robots are a waste of money. Eventually hospitals will realize this.

Citron Research

Looks expensive.

Overbought, and too much noise against the stock.

Two much controversy about safety, benefits, and possibly excessively marketing at a very uncertain time in politics and economy. For me, the downside risk outweighs the possible upside gain.

Citron Research. A solution in need of a problem. Forward trend of prostate cancer treatment decreasing due to lack of data showing improved outcomes.

Here is the summary of the citron report: The concerns seem legitimate: how it will play out less certain, but for a caps pick seems worth the risk

But the high earnings multiple conferred on Intuitive Surgical (NASDAQ:ISRG) does not
align with:
a track record of excessive and unjustified marketing claims
the utter lack of clinical evidence of superior medical outcomes when using its
product for surgery, and
the gathering storm of legal liability accruing to the company due to its failure to
adequately disclose risks prior to its technology causing adverse surgical outcomes,
scattered among the hundreds of thousands of surgeries performed with its robotic
surgery devices.

I think this Citron Report will lead to more selling for the next couple months. You can dispute the report or not, but the fact remains that the stocks they attack often become broken and drop much further. I would not be surprised if Citron comes out with another report in the near future. Just look at some others they have destroyed like QCOR, HLF, NUS, USNA, VVUS, and the other China small caps. I am not saying the report is right or wrong, but the truth is that does not matter at the moment.

Something smells fishy.

exposed to some lawsuits

isrg technology provides no long term medical benefit. it has not shown any improvement in long term outcome. it takes much longer to perform operations so that many specialties give up using it. it does improve recovery but not long term outcome. physicians and hospitals do not receive higher reimbursement for using it. in fact, it expensive and wastes hospital budget and taxpayer money on procedures that can be just as easily performed by laparoscopy. cms would unlikely approve reimbursement. although government waste does occur frequently.

The growth will slow as our wonderful new healthcare system becomes known. Too many uncertainties make this risky. Time for an adjustment soon.

P/E is out of this world!

Up too fast. Worst part of hospital spending cuts have yet to hit. Otherwise I'm a fan.

Overvalued compared to industry.

going down to 140 economy lol

Overvalued, for the moment.

With discretionary income being squeezed by high oil and food prices will people be willing to plunk down big bucks for cosmetic surgeries? I have to bet against it for the short term. If sales decrease by any significant % (15-20%) the shares will have to fall to a more reasonable valuation. March 2009 could see stock at $200. My only concern-- the wealthy are unaffected by rising costs and the poor don't understand the effects on their budget until after they have the procedure.